VIR-5500 ASCO GU update, VIR-5818 H2’26, ECLIPSE 1 Q4’26 + more hepatitis delta readouts. See more details here.

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium. Ensuring optimal treatment strategies for renal cell carcinoma (RCC) remains a key ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology “The breadth and depth of Decipher-focused data ...

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium. Following the 2025 Annual ASCO Genitourinary Cancers Symposium, Dr ...

YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...

Experimental drugs for renal and other genitourinary cancers are more likely to be approved when pharmaceutical companies collaborate on the research, according to a study in JCO Oncology Practice.

“How much does your medication cost?”: Assessing patient attitudes towards the costs of oncology medication to society. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

TTUHSC’s Thomas E. Hutson, D.O., Pharm.D., Ph.D., shared groundbreaking findings from the landmark CLEAR study Feb. 13-14 at the 2025 American Society of Clinical ...